Genzyme/Geltex Pharmaceuticals Joint Venture
Date Submitted: 09/10/2006 00:07:54
Early in 1997, Genzyme Corporation began negotiations with Geltex Pharmaceuticals in an attempt to launch a joint venture to market Geltex's first product, RenaGel. Geltex was a young biotech research company with only two products in its pipeline, and they didn't have the resources necessary to launch RenaGel on their own. Genzyme, on the other hand, was a quickly growing company that experienced revenues of $518 million in 1996. They were attracted to the joint venture with Geltex
Is this Essay helpful? Join now to read this particular paper
and access over 480,000 just like this GET BETTER GRADES
and access over 480,000 just like this GET BETTER GRADES
summarize:
*<Tab/>What is the likely enterprise value of the joint venture?<Tab/>($29,513,370)
*<Tab/>How much of the venture should Genzyme acquire?<Tab/>0%
*<Tab/>How much should Genzyme pay for its interest?<Tab/><Tab/>$0
Calculations for these numbers can be found in Appendix C, Exhibits 1 & 2
Need a custom written paper? Let our professional writers save your time.